Neomycin Sulfate, Polymyxin B Sulfate And Hydrocortisone

Prescription

ชื่อทางการค้า: Neomycin and Polymyxin B Sulfates and Hydrocortisone

รูปแบบยา

Drops

เส้นทางการให้ยา

AURICULAR (OTIC)

ผู้ผลิต

A-S Medication Solutions

About This Medication

DESCRIPTION Neomycin and polymyxin B sulfates and hydrocortisone otic suspension, USP is a sterile antibacterial and anti-inflammatory suspension for otic use. Each mL contains: Actives: neomycin sulfate equivalent to 3.5 mg neomycin base, polymyxin B sulfate equivalent to 10,000 polymyxin B units, and hydrocortisone 10 mg (1%); Inactives: cetyl alcohol (0.9%), polysorbate 80, propylene glycol, purified water. Sulfuric acid may be added to adjust pH (3.0 - 7.0). Preservative: thimerosal 0.01%. Neomycin sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of Streptomyces fradiae Waksman (Fam. Streptomycetaceae). It has a potency equivalent of not less than 600 mcg of neomycin standard per mg, calculated on an anhydrous basis. The structural formulae are: Polymyxin B sulfate is the sulfate salt of polymyxin B 1 and B 2 , which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formulae are: Hydrocortisone, 11β, 17, 21-trihydroxypregn-4-ene-3, 20-dione, is an anti-inflammatory hormone. Its structural formula is: ChemS ChemSt ChemStr

ส่วนประกอบออกฤทธิ์

ส่วนประกอบ	ความแรง
Hydrocortisone	-
Neomycin Sulfate	-
Polymyxin B Sulfate	-

ข้อบ่งใช้และการใช้งาน

INDICATIONS AND USAGE For the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the action of the antibiotics, and for the treatment of infections of mastoidectomy and fenestration cavities caused by organisms susceptible to the antibiotics.

ขนาดยาและวิธีการให้ยา

DOSAGE AND ADMINISTRATION Therapy with this product should be limited to 10 consecutive days. The external auditory canal should be thoroughly cleansed and dried with a sterile cotton applicator. For adults, 4 drops of the suspension should be instilled into the affected ear 3 to 4 times daily. For children, 3 drops are suggested because of the smaller capacity of the ear canal. The patient should lie with the affected ear upward and then the drops should be instilled. This position should be maintained for 5 minutes to facilitate penetration of the drops into the ear canal. Repeat, if necessary, for the opposite ear. If preferred, a cotton wick may be inserted into the canal and then the cotton may be saturated with the suspension. This wick should be kept moist by adding further suspension every 4 hours. The wick should be replaced at least once every 24 hours. SHAKE WELL BEFORE USING.

Side Effects Overview

ADVERSE REACTIONS Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS ). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. Stinging and burning have been reported rarely when this drug has gained access to the middle ear. To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

คำเตือนและข้อควรระวัง

WARNINGS Neomycin can induce permanent sensorineural hearing loss due to cochlear damage, mainly destruction of hair cells in the organ of Corti. The risk is greater with prolonged use. Therapy should be limited to 10 consecutive days (see PRECAUTIONS-General ). Patients being treated with eardrops containing neomycin should be under close clinical observation. Neomycin and polymyxin B sulfates and hydrocortisone otic suspension should not be used in any patient with a perforated tympanic membrane. Discontinue promptly if sensitization or irritation occurs. Neomycin sulfate may cause cutaneous sensitization. A precise incidence of hypersensitivity reactions (primarily skin rash) due to topical neomycin is not known. When using neomycin-containing products to control secondary infection in the chronic dermatoses, such as chronic otitis externa or stasis dermatitis, it should be borne in mind that the skin in these conditions is more liable than is normal skin to become sensitized to many substances, including neomycin. The manifestation of sensitization to neomycin is usually a low-grade reddening with swelling, dry scaling, and itching; it may be manifest simply as a failure to heal. Periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. These symptoms regress quickly on withdrawing the medication. Neomycin containing applications should be avoided for the patient thereafter.

ข้อห้ามใช้

CONTRAINDICATIONS This product is contraindicated in those individuals who have shown hypersensitivity to any of its components, and in herpes simplex, vaccinia, and varicella infections.

Frequently Asked Questions

INDICATIONS AND USAGE For the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the action of the antibiotics, and for the treatment of infections of mastoidectomy and fenestration cavities caused by organisms susceptible to the antibiotics.

DOSAGE AND ADMINISTRATION Therapy with this product should be limited to 10 consecutive days. The external auditory canal should be thoroughly cleansed and dried with a sterile cotton applicator. For adults, 4 drops of the suspension should be instilled into the affected ear 3 to 4 times daily. For children, 3 drops are suggested because of the smaller capacity of the ear canal. The patient should lie with the affected ear upward and then the drops should be instilled. This …

WARNINGS Neomycin can induce permanent sensorineural hearing loss due to cochlear damage, mainly destruction of hair cells in the organ of Corti. The risk is greater with prolonged use. Therapy should be limited to 10 consecutive days (see PRECAUTIONS-General ). Patients being treated with eardrops containing neomycin should be under close clinical observation. Neomycin and polymyxin B sulfates and hydrocortisone otic suspension should not be used in any patient with a perforated tympanic membrane. Discontinue promptly if sensitization or irritation …

CONTRAINDICATIONS This product is contraindicated in those individuals who have shown hypersensitivity to any of its components, and in herpes simplex, vaccinia, and varicella infections.

Neomycin Sulfate, Polymyxin B Sulfate And Hydrocortisone is a prescription medication. You will need a valid prescription from a licensed healthcare provider.

Similar Drops Products

Neomycin And Polymyxin B …

Brinzolamide

Ofloxacin Otic

Netarsudil

Neomycin And Polymyxin B …

Fluorometholone Acetate

Browse all Drops products →

References & Data Sources

• DailyMed — Neomycin Sulfate, Polymyxin B Sulfate And Hydrocortisone drug label (National Library of Medicine)
• openFDA — Neomycin Sulfate, Polymyxin B Sulfate And Hydrocortisone label data (U.S. Food & Drug Administration)
• RxNorm — RXCUI 310687 (NLM Normalized Drug Names)
• NDC Directory — Neomycin Sulfate, Polymyxin B Sulfate And Hydrocortisone (FDA National Drug Code)

ข้อจำกัดความรับผิดชอบทางการแพทย์

ข้อมูลในหน้านี้มีวัตถุประสงค์เพื่อการศึกษาเท่านั้น และไม่ควรใช้แทนคำแนะนำทางการแพทย์จากผู้เชี่ยวชาญ การวินิจฉัย หรือการรักษา

ควรขอคำแนะนำจากแพทย์หรือผู้ให้บริการด้านสุขภาพที่มีคุณสมบัติอื่นๆ เสมอ สำหรับคำถามใดๆ ที่คุณมีเกี่ยวกับภาวะทางการแพทย์หรือยา

แหล่งข้อมูล: DailyMed (NLM), openFDA, MFDS